Role of PCGEM1 in Breast Cancer

April 26, 2026 updated by: Rehab Mostafa Thabet Ahmed, Assiut University

Long Non-coding RNA: PCGEM1 as a Potential Marker for Tumorigenesis in Breast Cancer

This study examines certain molecular markers in breast cancer using blood and tissue samples from routine diagnostic biopsies. No extra procedures will be performed on patients. The goal is to improve understanding of disease mechanisms and identify potential targets for treatment

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This is an observational, case-control study designed to evaluate the expression of lncRNA PCGEM1 and its association with related molecular pathways, including RhoA, TRIAP1, and ferroptosis, in breast cancer patients. The study will include patients diagnosed with breast cancer and a matched control group.

No intervention will be performed as part of this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care, with no additional procedures carried out for research purposes.

Collected tissue samples will be processed for RNA extraction and subsequent molecular analysis to assess gene expression levels. The results will be analyzed to explore the potential role of PCGEM1 in tumor progression and its correlation with selected molecular pathways.

The findings of this study may contribute to a better understanding of breast cancer biology and help identify potential biomarkers or therapeutic targets.

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

18 years and older newly diagnosed female patients with histopathological confirmation of the diagnosis of breast cancer at any stage and matched control

Description

Inclusion Criteria:

  • Age: 18 years and older.
  • Newly diagnosed patients with histopathological confirmation of the diagnosis of breast cancer at any stage.

Exclusion Criteria:

  • Presence of any chronic diseases.
  • Previous history of breast cancer or other malignancies.
  • Evidence of distant metastasis at the time of diagnosis.
  • Prior treatment with chemotherapy or radiotherapy.
  • Incomplete clinical or laboratory data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
female breast cancer patients and matched control - no intervention
Device: No Biologics
No intervention will be performed in this study. Tissue samples will be obtained from routine diagnostic biopsies that are already indicated as part of standard clinical care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relative expression level of PCGEM1 marker in breast cancer tissue and blood sample
Time Frame: at base line
This outcome measures the relative expression level of PCGEM1 in breast cancer tissue and blood samples compared to control using quantitative real-time PCR (qRT-PCR). The results will be correlated with clinicopathological parameters.
at base line

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 5, 2026

Primary Completion (Estimated)

July 5, 2026

Study Completion (Estimated)

August 6, 2026

Study Registration Dates

First Submitted

April 26, 2026

First Submitted That Met QC Criteria

April 26, 2026

First Posted (Actual)

May 1, 2026

Study Record Updates

Last Update Posted (Actual)

May 1, 2026

Last Update Submitted That Met QC Criteria

April 26, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Breast cancer and PCGEM1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on No Biologics

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe